EBMT 2016

1:47
Why children should be offered choices in their treatment plans
Imelda Coyne
1:41
Why it is important to involve children and adolescents in treatment decision-making
Imelda Coyne
2:52
The role of proteasome inhibitors in multiple myeloma
Mohamad Mohty
3:11
Information is key: why patients need to be empowered to learn about their disease
John Murray
2:15
Assessment of response in multiple myeloma: next steps
Bruno Paiva
2:27
Highlights from EBMT 2016: Immunotherapy
Arnon Nagler
2:30
FLT3 inhibitors – their role in AML
Ali Bazarbachi
1:34
Next steps for novel treatments in multiple myeloma
Bruno Paiva
2:44
The TK008 Phase III trial on using donor lymphoctyes to treat patients with high-risk acute leukemia
Chiara Bonini
1:49
Drugs vs transplants in acute leukemias
Arnon Nagler
2:48
Virus-specific T cells – effectiveness, safety profile and use
Ann Leen
1:39
The significance of FLT3 mutations in AML
Ali Bazarbachi
3:35
Assessment of response in MM: challenges and advances
Bruno Paiva
2:30
Matched unrelated donor (MUD) transplantations for ALL and AML
Arnon Nagler
3:22
CAR T-cells and fast cars
Antonio Pagliuca
1:14
‘Off the shelf’ virus-specific T cells
Ann Leen
The content of VJHemOnc is intended for healthcare professionals